Clinical Trial

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-03-08; most recent amendment 2026-03-09.
Status change: Not Yet Recruiting → Recruiting 2022-05-18
Trial Details
NCT Number NCT05275686
Lead Sponsor Cedars-Sinai Medical Center
Collaborators: Sacramento Ear, Nose & Throat, Ochsner Health System, Indiana University
Conditions Eustachian Tube Dysfunction
Enrollment 80 participants
Start Date 2022-04-20
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-11